Global Single-Cell Genome Sequencing-based Cancer Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Single-Cell Genome Sequencing-based Cancer Market Analysis

The single-cell genome sequencing-based cancer market is rapidly expanding, driven by advancements in genomic technologies, rising cancer prevalence, and growing demand for personalized treatments. Single-cell genome sequencing has primarily been utilized in cancer research to examine critical factors such as intra-tumor heterogeneity, clonal evolution, invasion and metastasis, circulating tumor cells, and treatment response. These applications are contributing to substantial market expansion, especially in the fields of personalized cancer therapies and cutting-edge diagnostic solutions.

Ongoing innovations in sequencing technologies, such as improved throughput, accuracy, and cost-effectiveness, are making single-cell sequencing more accessible and efficient. New platforms, such as  10x Genomics' Chromium, PacBio's Onso, and Illumina’s NovaSeq, are pushing the boundaries of what can be achieved with single-cell analysis, supporting applications in cancer diagnostics, biomarker discovery, and drug development. Organizations such as the National Cancer Institute (NCI) and World Health Organization (WHO) are funding research projects that utilize single-cell sequencing technologies to uncover new insights into cancer biology, driving demand for cutting-edge sequencing tools.

Single-Cell Genome Sequencing-based Cancer Market Size

The global single-cell genome sequencing-based cancer market size was valued at USD 2.01 billion in 2024 and is projected to reach USD 15.73 billion by 2032, with a CAGR of 19.90% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Single-Cell Genome Sequencing-based Cancer Market Trends

“Integration of Multi-Omics Approaches”

A major trend in the single-cell sequencing market is the integration of multiple omics layers such as genomics, transcriptomics, proteomics, and epigenomics—into a unified analysis. This multi-omics approach provides a more holistic understanding of cancer biology at the cellular level. Single-cell multi-omics sequencing enables a more detailed exploration of how genetic, epigenetic, and proteomic alterations drive cancer progression, offering deeper insights into tumor behavior and potential therapeutic targets.

Report Scope and Single-Cell Genome Sequencing-based Cancer Market Segmentation

Single-Cell Genome Sequencing-based Cancer Market Definition

Single-cell sequencing is a method used to analyze genomes, transcriptomes, and epigenomes at the individual cell level. This technique uncovers cellular heterogeneity that is often overlooked in traditional sequencing of bulk samples, offering a transformative approach to understanding the genetic diversity and complexity underlying tumor progression. This technique provides a comprehensive view of the pan-cancer immune microenvironment, uncovering its intricate blueprint. Furthermore, it enables the identification of immune cell heterogeneity and their differentiation pathways, while also offering valuable insights for predicting tumor prognosis.

Single-Cell Genome Sequencing-based Cancer Market Dynamics

Drivers

• Increasing Demand for Personalized Cancer Therapies

The growing shift towards personalized medicine is a key driver of the single-cell sequencing market in cancer research. By enabling the analysis of individual tumor cells at the genomic level, single-cell sequencing offers deep insights into the heterogeneity of cancer, facilitating the development of tailored therapies. This capability is crucial in improving treatment outcomes and is fueling the demand for advanced genomic technologies in oncology. For instance, the application of single-cell sequencing in clinical trials has led to the identification of novel immune checkpoint targets, which have improved patient responses to immunotherapies, as seen in the success of drugs such as Keytruda (pembrolizumab). As personalized cancer treatments continue to gain traction, the adoption of single-cell sequencing technologies is expected to accelerate, driving further innovation and expansion in the market.

• Technological Advancements in Sequencing Platforms

Ongoing innovations in sequencing technologies have significantly reduced costs, enhanced accuracy, and boosted throughput, making single-cell genome sequencing more accessible in both research and clinical applications. These advancements are a major driver of market growth, as they enable broader adoption of the technology across oncology research and personalized treatment strategies. For instance, advancements in platforms such as 10x Genomics' Chromium Single Cell Gene Expression technology have revolutionized cancer research by offering higher resolution and cost-efficient ways to analyze thousands of individual tumor cells simultaneously thereby promoting the growth of the market.

Opportunities

• Expansion of Liquid Biopsy Applications

The ability of single-cell sequencing to detect circulating tumor cells (CTCs) and cell-free DNA (cfDNA) creates substantial opportunities in the non-invasive detection, monitoring, and treatment assessment of cancer. The growing adoption of liquid biopsy, as a less invasive and more cost-effective alternative to traditional tissue biopsies, is fueling market growth. This approach offers a promising solution for early cancer detection and continuous monitoring, while simultaneously reducing patient discomfort and lowering healthcare costs. As these technologies evolve, they present significant potential to transform cancer diagnostics and management, driving further advancements in precision oncology. These innovations are not only shaping the future of cancer care but also creating new avenues for growth in the market globally.

• Increasing Focus on Tumor Microenvironment (TME) Profiling

Single-cell sequencing is increasingly crucial in understanding the tumor microenvironment (TME) and its impact on cancer progression and resistance to therapy. This growing field of research presents significant opportunities for the development of novel cancer immunotherapies and more effective treatment strategies. As a result, it is driving market potential in personalized cancer care and targeted therapies, offering the chance to tailor treatments to individual patients for improved outcomes. The insights gained from single-cell sequencing are opening new pathways for the development of highly specific and effective cancer treatments. The continued advancements in this technology are expected to revolutionize cancer therapy, offering substantial growth opportunities in the oncology market and transforming the landscape of precision medicine.

Restraints/Challenges

• High Cost of Single-Cell Sequencing Technologies

The high cost of single-cell sequencing remains a significant barrier, limiting its wider adoption in clinical settings, especially in low-resource regions. For instance, in countries with limited healthcare budgets, such as many in sub-Saharan Africa, the cost of implementing single-cell sequencing technologies makes it challenging to integrate these methods into routine cancer diagnostics and treatment. Additionally, the complex nature of the technology requires specialized expertise, which further increases operational costs and slows its integration into standard clinical workflows. This financial burden creates a bottleneck in scaling the technology for broader use. As a result, the high costs and technical challenges continue to restrict the growth of the market, particularly in underserved areas.

• Regulatory and Ethical Concerns

The regulatory approval process for single-cell sequencing technologies, especially for clinical applications, can be time-consuming and complicated. For instance, obtaining approval from regulatory bodies such as the FDA or EMA for new sequencing-based diagnostics requires extensive clinical validation, which can delay market entry. Additionally, ethical concerns surrounding genetic data privacy, particularly in relation to patient consent and the handling of sensitive genetic information, present significant challenges. There is also concern about the potential for genomic data misuse in personalized treatments, which could undermine public trust in these technologies. These ethical and regulatory hurdles could slow the widespread adoption of single-cell sequencing in clinical practice and impede market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Single-Cell Genome Sequencing-based Cancer Market Scope

The market is segmented on the basis of product type, technology, workflow, disease area, application and end-use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Instruments and
• Reagents

Technology

• Next-generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Quantitative Polymerase Chain Reaction (qPCR)
• Microarray
• Microbial Detection Array (MDA)

Workflow

• Genomic Analysis
• Single Cell Isolation
• Sample Preparation

Disease Area

• Cancer
• Immunology
• Prenatal Diagnosis
• Neurobiology
• Microbiology
• Others

Application

• Circulating Cells
• Cell Differentiation/Reprogramming
• Genomic Variation
• Subpopulation Characterization
• Others

End-use

• Academic & Research Laboratories
• Biotechnology & Biopharmaceutical Companies
• Clinics and Others

Single-Cell Genome Sequencing-based Cancer Market Regional Analysis

The market is analysed and market size insights and trends are provided by product type, technology, workflow, disease area, application and end-use. as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Italy, Spain, Denmark, Sweden, Norway, Rest of Europe in Europe, China, Japan, India, South Korea, Australia, Thailand, Indonesia, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Kuwait, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the single-cell genome sequencing market, driven by increased research and development funding and a growing adoption of genomic analysis products. The region's strong infrastructure for scientific innovation, coupled with the presence of leading market players, further accelerates the growth and expansion of the market.

Asia-Pacific is expected to witness the highest CAGR during the forecast period, primarily driven by the growing geriatric population, which is leading to a higher incidence of chronic diseases. Moreover, the region is likely to benefit from significant advancements in healthcare infrastructure, as developing countries focus on boosting their economies and enhancing healthcare capabilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Single-Cell Genome Sequencing-based Cancer Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Single-Cell Genome Sequencing-based Cancer Market Leaders Operating in the Market Are:

• 10x Genomics. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• BD (U.S.)
• BGI (China)
• Bio-Rad Laboratories, Inc. (U.S.)
• Bruker (U.S.)
• Cell Microsystems (U.S.)
• Danaher Corporation (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Illumina, Inc. (U.S.)
• MCKESSON CORPORATION (U.S.)
• Mission Bio. (U.S.)
• Novogene Co., Ltd. (China)
• Oxford Nanopore Technologies plc. (U.K.)
• PacBio. (U.S.)
• Promega Corporation (U.S.)
• QIAGEN (Germany)
• Siemens Healthineers AG (Germany)
• Standard BioTools (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Veradigm LLC (U.S.)

Latest Developments in Single-Cell Genome Sequencing-based Cancer Market

• In October 2024, PacBio entered a Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS) to accelerate cancer research in Asia. The project will use PacBio's Onso short-read and Kinnex long-read sequencing technologies, focusing on profiling common cancers in the region, particularly through single-cell RNA sequencing
• In June 2024, Bio-Rad Laboratories, Inc. announced the launch of the ddSEQTM Single-Cell 3' RNA-Seq Kit and complementary Omnition v1.1 analysis software for single-cell transcriptome and gene expression research. The ddSEQ Single-Cell 3' RNA-Seq Kit delivers high-quality single-cell 3' RNA-Seq libraries in a fast, efficient, and affordable workflow, allowing researchers to easily conduct single-cell gene expression and regulation analyses
• In May 2023, Pfizer and Thermo Fisher Scientific Inc. announced a collaboration aimed at expanding local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients. This initiative will target over 30 countries across Latin America, Africa, the Middle East, and Asia, where advanced genomic testing has been previously limited or inaccessible
• In July 2023, Institut Curie and Agilent introduced an advanced comprehensive genomic profiling kit designed to identify key genetic abnormalities driving cancer. The kit's functionality was demonstrated in the SHIVA02 clinical trial and is now being utilized in routine practice as part of the molecular RCP conducted by Institut Curie’s Department of Drug Development and Innovation
• In April 2020, Mission Bio, Inc. announced a partnership with Agilent Technologies to promote the adoption of Mission Bio's Tapestri Platform, the first and only multi-omic device capable of analyzing both DNA and protein at the single-cell level. This collaboration aims to provide the necessary tools to develop new treatments and potentially cures for cancer

SKU-73354